


L-Eflornithine

Cat. No.:	HY-B0744C
CAS No.:	66640-93-5
Molecular Formula:	C ₆ H ₁₂ F ₂ N ₂ O ₂
Molecular Weight:	182.17
Target:	Parasite
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	L-Eflornithine (L-DFMO) is an enantiomer of Eflornithine. L-Eflornithine is an irreversible ornithine decarboxylase (ODC) inhibitor with a K_D of $1.3 \pm 0.3 \mu\text{M}$, and a K_{inact} of $0.15 \pm 0.03 \text{ min}^{-1}$ [1].
IC₅₀ & Target	KD: $1.3 \pm 0.3 \mu\text{M}$ (Ornithine decarboxylase, ODC)[1]
In Vitro	Eflornithine (D/L-DFMO) is an inhibitor of ODC, the first enzyme in eukaryotic polyamine biosynthesis. Both enantiomers of Eflornithine (DFMO) irreversibly inactivate ODC. Both Eflornithine enantiomers (L-Eflornithine and D-Eflornithine) suppress ODC activity in a time- and concentration-dependent manner. The inhibitor dissociation constant (K_D) values for the formation of enzyme-inhibitor complexes are 28.3 ± 3.4 , 1.3 ± 0.3 and $2.2 \pm 0.4 \mu\text{M}$ respectively for D-Eflornithine, L-Eflornithine and Eflornithine. The inhibitor inactivation constants (K_{inact}) for the irreversible step were 0.25 ± 0.03 , 0.15 ± 0.03 and $0.15 \pm 0.03 \text{ min}^{-1}$ respectively for D-Eflornithine, L-Eflornithine and Eflornithine. Treatment of human colon tumour-derived HCT116 cells with either L-Eflornithine or D-Eflornithine decreases the cellular polyamine contents in a concentration-dependent manner[1]. The enantiomers display different potencies in vitro, with the L-enantiomer having up to a 20-fold higher affinity for the target enzyme ornithine decarboxylase[2]. The L-Eflornithine also appears to be more potent in cultured <i>T. brucei gambiense</i> parasites[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	The more potent L-Eflornithine is present at much lower concentrations in both plasma and cerebrospinal fluid (CSF) than those of the D-Eflornithine. The plasma concentrations of L-Eflornithine are on average 52% of the D-enantiomer concentrations. The typical oral clearances of L-Eflornithine and D-eflornithine are 17.4 and 8.23 liters/h, respectively[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Qu N, et al. Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine. *Biochem J.* 2003 Oct 15;375(Pt 2):465-70.

[2]. Jansson-Löfmark R, et al. Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage *Trypanosoma brucei gambiense* sleeping sickness. *Antimicrob Agents Chemother.* 2015 Feb;59(2):1299-307.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA